CA2438204A1 - Ascorbic acid analogs for metalloradiopharmaceuticals - Google Patents

Ascorbic acid analogs for metalloradiopharmaceuticals Download PDF

Info

Publication number
CA2438204A1
CA2438204A1 CA002438204A CA2438204A CA2438204A1 CA 2438204 A1 CA2438204 A1 CA 2438204A1 CA 002438204 A CA002438204 A CA 002438204A CA 2438204 A CA2438204 A CA 2438204A CA 2438204 A1 CA2438204 A1 CA 2438204A1
Authority
CA
Canada
Prior art keywords
radiopharmaceutical
formula
biomolecule
radiopharmaceutical composition
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438204A
Other languages
English (en)
French (fr)
Inventor
Shuang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438204A1 publication Critical patent/CA2438204A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002438204A 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals Abandoned CA2438204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27138901P 2001-02-26 2001-02-26
US60/271,389 2001-02-26
PCT/US2002/005155 WO2002067859A2 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Publications (1)

Publication Number Publication Date
CA2438204A1 true CA2438204A1 (en) 2002-09-06

Family

ID=23035343

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438204A Abandoned CA2438204A1 (en) 2001-02-26 2002-02-22 Ascorbic acid analogs for metalloradiopharmaceuticals

Country Status (12)

Country Link
US (1) US6713042B2 (https=)
EP (1) EP1365813A4 (https=)
JP (1) JP2004529884A (https=)
CN (1) CN1503680A (https=)
AU (1) AU2002253999A1 (https=)
BR (1) BR0207315A (https=)
CA (1) CA2438204A1 (https=)
CZ (1) CZ20032597A3 (https=)
HU (1) HUP0304083A2 (https=)
IL (1) IL157359A0 (https=)
MX (1) MXPA03007595A (https=)
WO (1) WO2002067859A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305463A1 (de) * 2003-02-04 2004-08-12 Schering Ag Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel
US20050089471A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20050089470A1 (en) * 2003-10-24 2005-04-28 Johnson Bruce F. Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
GB0427392D0 (en) * 2004-12-15 2005-01-19 Amersham Plc Stabilised 99mTc compositions
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
RU2008150377A (ru) * 2006-05-19 2010-06-27 Нихон Меди-Физикс Ко., Лтд. (Jp) Новое соединение, обладающее сродством к амилоиду
CN101501033B (zh) * 2006-06-21 2012-08-01 通用电气医疗有限公司 对淀粉状蛋白具有亲和性的化合物
PL2029178T3 (pl) * 2006-06-21 2012-08-31 Ge Healthcare Ltd Produkty radiofarmaceutyczne
WO2008056481A1 (en) * 2006-11-09 2008-05-15 Nihon Medi-Physics Co., Ltd. Radioactive diagnostic imaging agent
KR20090091287A (ko) * 2006-11-17 2009-08-27 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
EP2098522B1 (en) * 2006-11-30 2011-10-19 Nihon Medi-Physics Co., Ltd. Compounds having affinity for amyloid
PL2106808T3 (pl) * 2006-12-21 2018-07-31 Nihon Medi-Physics Co., Ltd. Promieniotwórczy znacznik do obrazowania diagnostycznego zawierający kwas 1-amino-3-[18F]fluorocyklobutanokarboksylowy
TWI406674B (zh) 2007-02-13 2013-09-01 日本藥學物理公司 Method for manufacturing diagnostic radiographic diagnostic agents
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
TW200918102A (en) * 2007-10-24 2009-05-01 Nihon Mediphysics Co Ltd Novel compound having affinity for amyloid
CN101909658A (zh) * 2007-10-30 2010-12-08 日本医事物理股份有限公司 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法
KR20100089858A (ko) * 2007-10-30 2010-08-12 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법
WO2009073698A1 (en) * 2007-12-04 2009-06-11 Bracco Imaging S.P.A. Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients
RU2011112946A (ru) * 2008-09-05 2012-10-10 Молекьюлар Инсайт Фармасьютикалз, Инк. (Us) Фармацевтическая композиция радиойодированного бензамидного производного и способы ее получения
FR2942227B1 (fr) * 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
KR101602992B1 (ko) 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US9321095B2 (en) 2010-06-30 2016-04-26 General Electric Company Apparatuses and methods for cutting porous substrates
WO2013093099A1 (en) * 2011-12-22 2013-06-27 Piramal Imaging Sa Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof
CN104470547B (zh) 2012-05-24 2018-01-26 未来化学株式会社 利用筒状物合成放射性药物的方法
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
JP2016510342A (ja) * 2013-02-15 2016-04-07 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 腫瘍画像化のためのキット
KR101652204B1 (ko) * 2014-11-27 2016-08-29 (주)셀트리온 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 포함하는 화장료 조성물
TWI604853B (zh) * 2016-05-03 2017-11-11 行政院原子能委員會核能研究所 放射免疫複合體、診療劑及套組
CN107167540B (zh) * 2017-07-08 2019-07-30 万舒（北京）医药科技有限公司 测定人尿液生物样品中的DTPA-Zn的方法
KR102207372B1 (ko) * 2020-03-31 2021-01-27 재단법인 아산사회복지재단 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL42204A (en) * 1972-05-08 1976-09-30 Solco Basel Ag Process and apparatus for the manufacture of injectable radionuclide preparations
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
DK0422713T3 (da) * 1989-10-09 1995-04-10 Unilever Plc Spiseligt smøremateriale
DK0600992T3 (da) * 1991-08-29 2000-10-09 Mallinckrodt Medical Inc Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof

Also Published As

Publication number Publication date
EP1365813A4 (en) 2006-03-22
JP2004529884A (ja) 2004-09-30
WO2002067859A2 (en) 2002-09-06
IL157359A0 (en) 2004-02-19
US6713042B2 (en) 2004-03-30
WO2002067859A3 (en) 2002-11-28
US20020122769A1 (en) 2002-09-05
CN1503680A (zh) 2004-06-09
MXPA03007595A (es) 2003-12-04
HUP0304083A2 (hu) 2004-03-29
BR0207315A (pt) 2004-02-10
EP1365813A2 (en) 2003-12-03
AU2002253999A1 (en) 2002-09-12
CZ20032597A3 (cs) 2004-12-15

Similar Documents

Publication Publication Date Title
US6713042B2 (en) Ascorbic acid analogs for metalloradiopharmaceuticals
Sarko et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases
US5866097A (en) Technetium-99m labeled peptides for imaging
Velikyan et al. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature
US20020122768A1 (en) Stable radiopharmaceutical compositions and methods for preparation thereof
US6565828B2 (en) Macrocyclic chelants for metallopharmaceuticals
Guhlke et al. 188Re-and 99mTc-MAG3 as prosthetic groups for labeling amines and peptides: approaches with pre-and postconjugate labeling
SI9620076A (sl) Stabilni reagenti za pripravo radiofarmacevtikov
CA3171753A1 (en) Stable formulations for radionuclide complexes
US6534038B2 (en) Ternary ligand complexes useful as radiopharmaceuticals
US6517814B2 (en) Macrocyclic chelants useful for metallopharmaceuticals
Eberle et al. Receptor-mediated tumor targeting with radiopeptides: Part 1. General principles and methods
Läppchen et al. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
JP2002510705A (ja) 感染および炎症の撮像、ならびに癌の撮像および治療のための放射性医薬品
M Rey Radiometal complexes in molecular imaging and therapy
Boros et al. Coordination chemistry and ligand design in the development of metal based radiopharmaceuticals
US7319149B2 (en) Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US20020094316A1 (en) Polypodal chelants for metallopharmaceuticals
US6251364B1 (en) Ternary ligand complexes useful as radiopharmaceuticals
Klenner et al. Labeled rhenium complexes: radiofluorination, α-MSH cyclization, and deuterium substitutions
US7317104B2 (en) Chelants and macrocyclic metal complex radiopharmaceuticals thereof
Bartholomae et al. The Role of Fundamental Coordination Chemistry in the Development of Radioimaging Agents
Decristoforo et al. Technetium-99m labelling of RGD peptides targeting integrin receptors: Comparison of different conjugates of cRGDyK utilizing different technetium-99m cores
Abrunhosa et al. Radiopharmaceuticals: Development and Main Applications
HK40120870A (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued